Company news
Cardiol Therapeutics Inc. Class A (TSX:CRDL) news
Cardiol Therapeutics Inc. Class A news releases on 6ix. Latest, Aug 9, 2021: Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"
Press releases — page 3
Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"
August 9, 2021
Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman
July 7, 2021
Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting
June 30, 2021
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT
June 28, 2021
Cardiol Therapeutics Closes $22 Million Bought Deal Offering
May 12, 2021
IIROC Trade Resumption - CRDL
May 6, 2021
IIROC Trading Halt - CRDL
May 5, 2021
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
April 28, 2021
Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)
April 12, 2021
Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A
April 1, 2021
Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer
March 30, 2021
Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options
March 2, 2021
TMX Group, Cardiol Therapeutics, C-Suite at The Open
February 4, 2021
Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
January 21, 2021
Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences
January 7, 2021
Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx(TM)
December 22, 2020
Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
December 15, 2020
Cardiol Therapeutics' Cortalex(TM) CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.
October 20, 2020
FDA Approves Landmark COVID/Heart/CBD Clinical Trial -- SECFilings.com
September 30, 2020
Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial
September 25, 2020
Cannabidiol Phase 1 Clinical Trial Launches, Targeting Inflammatory Heart Condition -- SECFilings.com
September 16, 2020
Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
September 15, 2020
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx(TM)
August 26, 2020
Orphan Drug Designation Is Proven Path for CBD -- SECFilings.com
August 5, 2020
Heart Health and COVID-19: Fighting Inflammation May be Key -- SECFilings.com
July 15, 2020
Cannabis & CBD Biopharma Investor Presentations Now Available for On-Demand Viewing
July 10, 2020
Live Investor Conference & Webinar: Cannabis & CBD Biopharma Industry Companies Present July 9th
July 7, 2020
Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor
June 29, 2020
David Elsley Files Early Warning Report for Cardiol Therapeutics
June 25, 2020
Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option
June 4, 2020
Cardiol Therapeutics Reports 2020 AGM Results
June 2, 2020
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 1st at 4:30 p.m. EDT
May 29, 2020
Cardiol Therapeutics Announces Increase to Previously Announced Bought Deal Public Offering
May 14, 2020
Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering
May 13, 2020
Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19
May 6, 2020
Cardiol Therapeutics Announces Study Demonstrating its Proprietary Nanotechnology Targets Fibrous Tissue in the Heart
April 14, 2020
Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure
April 1, 2020
Cardiol Therapeutics Announces Filing of 2019 Year-End Financial Statements and MD&A
March 26, 2020
Cardiol Therapeutics Signs Supplier Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc.
March 18, 2020
Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation
March 5, 2020
Cardiol Therapeutics' Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada
January 15, 2020
Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor
December 18, 2019
Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors
December 3, 2019
Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency
November 25, 2019
Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100
November 19, 2019
Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100
October 1, 2019
Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing
September 16, 2019
/R E P E A T -- Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12th/
September 5, 2019
Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th
September 5, 2019
Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
July 25, 2019